RhumbLine Advisers’s Prelude Therapeutics PRLD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-15,499
| Closed | -$11.9K | – | 4231 |
|
|
2025
Q1 | $11.9K | Sell |
15,499
-151,331
| -91% | -$116K | ﹤0.01% | 3807 |
|
|
2024
Q4 | $213K | Buy |
166,830
+154,826
| +1,290% | +$197K | ﹤0.01% | 3165 |
|
|
2024
Q3 | $24.8K | Sell |
12,004
-9,561
| -44% | -$19.8K | ﹤0.01% | 3794 |
|
|
2024
Q2 | $82.2K | Buy |
21,565
+399
| +2% | +$1.52K | ﹤0.01% | 3567 |
|
|
2024
Q1 | $100K | Buy |
21,166
+763
| +4% | +$3.62K | ﹤0.01% | 3447 |
|
|
2023
Q4 | $87.1K | Sell |
20,403
-13,412
| -40% | -$57.3K | ﹤0.01% | 3494 |
|
|
2023
Q3 | $104K | Buy |
33,815
+3,996
| +13% | +$12.3K | ﹤0.01% | 3447 |
|
|
2023
Q2 | $134K | Buy |
+29,819
| New | +$134K | ﹤0.01% | 3415 |
|
|
2022
Q2 | – | Sell |
-10,050
| Closed | -$69K | – | 3205 |
|
|
2022
Q1 | $69K | Buy |
+10,050
| New | +$69K | ﹤0.01% | 2948 |
|
|
2021
Q4 | – | Sell |
-9,275
| Closed | -$290K | – | 3020 |
|
|
2021
Q3 | $290K | Buy |
9,275
+500
| +6% | +$15.6K | ﹤0.01% | 2779 |
|
|
2021
Q2 | $251K | Sell |
8,775
-886
| -9% | -$25.3K | ﹤0.01% | 2858 |
|
|
2021
Q1 | $419K | Buy |
9,661
+115
| +1% | +$4.99K | ﹤0.01% | 2569 |
|
|
2020
Q4 | $683K | Buy |
+9,546
| New | +$683K | ﹤0.01% | 2311 |
|